Friday, November 29, 2024 The recently opened CCTG PR25 clinical trial uses a personalized medicine approach to investigate and evaluate markers to determine which metastatic prostate cancer patients would benefit from treatment with carboplatin a drug used in other cancers but not routinely used in prostate cancer. “By conducting this trial, we aim to expand the use of biomarker directed therapies for advanced prostate cancer, with the ultimate goal of improving the lives of patients suffering from this disease,” says Dr Michael Kolinsky, Medical Oncologist at the Cross Cancer Institute and CCTG PR25 study chair.A quarter of prostate cancer patients have alterations in their genes that normally repair damage. These genes are called DNA damage response (DDR) genes which make cancer cells sensitive to a form of chemotherapy called platinum-based chemotherapy (PBC)."This important clinical trial uses existing genetic testing to enable investigation of established treatments in patients with genomic alterations to determine if these treatments will improve their outcomes," says Dr Mariam Jafri, CCTG Senior Investigator.The purpose of this study is to compare the effects of a new drug compared to the current standard treatment for this disease. The study will specifically test whether platinum-based chemotherapy used in combination with a non-platinum-based drug improves overall survival for advanced prostate cancer patients with DNA damage response gene alterations. “I received surgery and Androgen Deprivation Therapy for Prostate Cancer several years ago. While my treatment has been successful, for a group of patients, their cancer continues to grow,” says Bill Richardson, CCTG Patient Representative. “I think this is an important trial which offers the possibility of a new treatment that could improve the duration and quality of life for this group of patients.” PR25 trial patient information >PR25 members trial information > Dr Michael Kolinsky CCTG PR25 study chair Bill Richardson, CCTG Patient Representative Dr Mariam Jafri, CCTG Senior Investigator
